Changes in esophageal motility after porfimer sodium photodynamic therapy for Barrett's dysplasia and mucosal carcinoma

Diseases of the Esophagus

Volumn 19, Issue 5, 2006, Pages 335-339

  Shah, A K ^a   Wolfsen, H C ^a   Hemminger, L L ^a   Shah, A A ^a   DeVault, K R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aperistalsis; Endoscopic ablation; Ineffective esophageal motility; Porfimer sodium

Indexed keywords

PHOTOFRIN; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; ENDOSCOPIC THERAPY; ESOPHAGUS CARCINOMA; ESOPHAGUS FUNCTION; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MANOMETRY; ESOPHAGUS MOTILITY; ESOPHAGUS SPASM; FEMALE; HUMAN; MALE; PATIENT REFERRAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; DIHEMATOPORPHYRIN ETHER; ESOPHAGEAL MOTILITY DISORDERS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MANOMETRY; MIDDLE AGED; MUCOUS MEMBRANE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES;

EID: 33748706574     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2006.00592.x     Document Type: Article

References (27)

1. Cameron A J, Ott B J, Payne W S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9.
2. Haggitt R C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25: 982-93.
3. Spechler S J. Clinical practice. Barrett's Esophagus. N Engl J Med 2002; 346: 836-42.
4. Weston A P, Sharma P, Mathur S et al. Risk stratification of Barrett's esophagus: Updated prospective multivariate analysis. Am J Gastroenterol 2004; 99: 1657-66.
5. Dolmans D E, Fukumura D, Jain R K. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3: 380-7.
6. Wolfsen H C. Present Status of Photodynamic Therapy for High-Grade Dysplasia in Barrett's Esophagus. J Clin Gastroenterol 2005; 39: 189-202.
7. Wolfsen H C, Hemminger L L, DeVault K R. Recurrent Barrett's esophagus and adenocarcinoma after esophagectomy. BMC Gastroenterol 2004; 4: 18.
8. Sarela A I, Hick D G, Verbeke C S et al. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Arch Surg 2004; 139: 547-51.
9. Iwakiri K, Sugiura T, Hayashi Y et al. Esophageal motility in Japanese patients with Barrett's esophagus. J Gastroenterol 2003; 38: 1036-41.
10. Zentilin P, Conio M, Mele M R et al. Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. Aliment Pharmacol Ther 2002; 16: 893-8.
11. Malhi-Chowla N, Wolfsen H C, DeVault K R. Esophageal dysmotility in patients undergoing photodynamic therapy. Mayo Clin Proc 2001; 76: 987-9.
12. Wolfsen H C, Hemminger L L, Wallace M B et al. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther 2004; 20: 1125-31.
13. Overholt B F, Panjehpour M, Halberg D L. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58: 183-8.
14. Al-Kasspooles M F, Hill H C, Nava H R et al. High-grade dysplasia within Barrett's esophagus: Controversies regarding clinical opinions and approaches. Ann Surg Oncol 2002; 9: 222-7.
15. Prosst R L, Wolfsen H C, Gahlen J. Photodynamic therapy for esophageal diseases: A clinical update. Endoscopy 2003; 35: 1059-68.
16. McCaughan J S Jr, Ellison E C, Guy J T et al. Photodynamic therapy for esophageal malignancy: A prospective twelve-year study. Ann Thorac Surg 1996; 62: 1005-9.
17. Ward E, Wolfsen H C. Clinical use of PDT for treatment and photodetection in gastroenterology. In: Nalwa, H, ed. Handbook of Photochemistry and Photobiology. American Scientific Publishers, Stevenson Ranch, CA. 2001.
18. Panjehpour M, Overholt B F, Phan M N et al. Optimization of light dosimetry for photodynamic therapy of Barrett's esophagus: Efficacy vs. incidence of stricture after treatment. Gastrointest Endosc 2005; 61: 13-8.
19. Overholt B F. Acid suppression and reepithelialization after ablation of Barrett's esophagus. Dig Dis 2000; 18: 232-9.
20. Byrne P J, Mulligan E D, O'Riordan J et al. Impaired visceral sensitivity to acid reflux in patients with Barrett's esophagus. The role of esophageal motility*. Dis Esophagus 2003; 16: 199-203.
21. Brandt M G, Darling G E, Miller L. Symptoms, acid exposure and motility in patients with Barrett's esophagus. Can J Surg 2004; 47: 47-51.
22. Fass R, Sampliner R E, Malagon I B et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14: 597-602.
23. Gerson L B, Boparai V, Ullah N et al. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004; 20: 637-43.
24. Jankowski J A, Anderson M. Review article: Management of oesophageal adenocarcinoma - control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Aliment Pharmacol Ther 2004; 20: 71-80; discussion 95-6.
25. Theisen J, Peters J H, Stein H J. Experimental evidence for mutagenic potential of duodenogastric juice on Barrett's esophagus. World J Surg 2003; 27: 1018-20.
26. Stein H J, Kauer W K, Feussner H et al. Bile reflux in benign and malignant Barrett's esophagus: Effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg 1998; 2: 333-41.
27. Mason R J, Bremner C C. Motility differences between long-segment and short-segment Barrett's esophagus. Am J Surg 1993; 165: 686-9.